Unicycive Therapeutics, Inc. Common Stock (UNCY) Stock Price, Quote & AI Analysis

Live UNCY stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Unicycive Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Unicycive Therapeutics, Inc. Common Stock (UNCY), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.

UNCY
Unicycive Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
7.250000
High
7.640000
Low
7.250000
Volume
664,879
VWAP
-
Market Cap
$192,240,194.40
52W Range
$3.71 - $11.00
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Aug 12, 2026 Q2
Market
EPS Estimate: $-0.461
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Unicycive Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Unicycive Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Company Details
Market Cap
$198.38M
Shares Outstanding
26,700,027
Weighted Shares Outstanding
26,700,027
CEO
Shalabh Gupta
Address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
Employees
22
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and indicators

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Unicycive Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...